| Mesothelioma Vaccine Jump Starts Immunity |
Scientists studying a vaccine for mesothelioma have published some of their most important preliminary data in the respected medical journal Lung Cancer.
Mesothelioma, a cancer of the organ linings caused by asbestos exposure, is highly resistant to conventional treatments. Not only does it grow quickly, but its shape makes detection and removal difficult. Unlike some other types of solid tumors which may grow in a mass, mesothelioma tumors tend to spread out in a sheet-like formation across membranes.
The UK scientists have been experimenting with a new method for targeting and destroying mesothelioma tumors, regardless of their shape. 5T4 is an antigen overexpressed by several kinds of cancer cells. The researchers tested for 5T4 in mesothelioma cells taken from 11 lab-grown cell samples, 21 tumor biopsies, and 11 samples of the pleural fluid of mesothelioma patients. For comparison, they also tested the 5T4 antibody levels in the plasma of healthy donors.
The research team confirmed that 5T4 was overexpressed in all of the mesothelioma cells tested. Next, they exposed samples of mesothelioma cells to 5T4-specific killer T-cells – the same kind of cells produced by the immune system to destroy invaders. In the lab, the 5T4-targeting killer T-cells were able to kill four out of six of the mesothelioma cell lines tested.
"We conclude that 5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognized by 5T4-specific Cytotoxic T-cells," wrote the researchers in a recent published report. Their findings have since been translated into a Phase II clinical trial using 5T4-targeted therapies in mesothelioma patients. The patients are being treated with a vaccine called TroVax which activates their killer T-cells to find and destroy mesothelioma cells overexpressing the 5T4 antigen.
The TroVax mesothelioma study is an example of the treatment approach known as immunotherapy. Unlike other types of mesothelioma treatments, such as chemotherapy and radiotherapy, immunotherapy is relatively non-toxic and theoretically capable of killing the targeted cells anywhere in the body. Because it is designed to 'teach' the body's immune system which cells to target, the immune system 'memory' may help keep mesothelioma from returning.
New therapeutic agents are particularly important for mesothelioma, because it is so aggressive and because there are so few effective treatment options available. Two to three thousand Americans and 2,000 UK residents are diagnosed with mesothelioma every year.
Sources:
Al-Taei, S et al, "Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma", April 10, 2012, Lung Cancer, Epub ahead of print.
TroVax information, Oxford BioMedica website, Accessed 4/15/12.
© Surviving Mesothelioma and Cancer Monthly. All rights reserved.
DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.
